uniQure N.V. - Ordinary Shares (QURE) News
Filter QURE News Items
QURE News Results
|Loading, please wait...
QURE News Highlights
- QURE's 30 day story count now stands at 5.
- Over the past 11 days, the trend for QURE's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- AMT, CSL and ASH are the most mentioned tickers in articles about QURE.
Latest QURE News From Around the Web
Below are the latest news stories about UNIQURE NV that investors may wish to consider to help them evaluate QURE as an investment opportunity.
The biotechnology company’s share price fell more than 10% Tuesday after the disclosure of more data from a small study.
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural history of the disease ~ ~ Mean CSF NfL continue to demonstrate favorable trends with low-dose patients below baseline at 30 months and high-dose patients near baseline at 18 months ~ ~ AMT-130 continues to be generally well-tolerated across both doses ~ ~ Data support continuing clinical development of AMT-
CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B
Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) today announced the three-year results from the pivotal HOPE-B study confirming continued long-term durability and safety of HEMGENIX® (etranacogene dezaparvovec-drlb) following a one-time infusion in people living with hemophilia B. The data showing that a one-time infusion of HEMGENIX offers elevated and sustained factor IX activity levels for years were presented in an oral presentation at the 65th American Society of Hematology (ASH) A
In this piece, we will take a look at the 12 best genomics stocks to buy now. If you want to skip our introduction to the genomics industry and all the latest trends, then take a look at 5 Best Genomics Stocks To Buy Now. If there’s one thing that can be said with certainty […]
LEXINGTON, Mass. and AMSTERDAM, Dec. 08, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the grant of inducement equity awards to newly hired employees. The company granted equity awards to 28 employees as a material inducement to commencing their employment. In the aggregate, those employees received 142,300 restricted share units and options to purchase 52,500 ordinar
uniQure N.V. ( NASDAQ:QURE ) shareholders should be happy to see the share price up 24% in the last month. But that...
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
Patient enrollment expected to begin in first half of 2024LEXINGTON, Mass. and AMSTERDAM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for AMT-191, the Company’s gene therapy candidate for Fabry disease. AMT-191 comprises an AAV5 vector that delivers a
If you are hungry for high-risk returns, then these micro-cap stocks to buy could be your winning ticket to future yields.
Key Insights The projected fair value for uniQure is US$7.03 based on 2 Stage Free Cash Flow to Equity Current share...
The mean of analysts' price targets for uniQure (QURE) points to a 405.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.